Article

Targeting the LIPH-CD36 axis potentiates CDK4/6 inhibition in ER+ breast cancer

2026-08-07

Abstract excerpt

<title>Abstract</title> <p>ER+/HER2 − breast cancer is commonly treated with endocrine therapy combined with CDK4/6 inhibitors (CDK4/6i), including palbociclib, ribociclib, and abemaciclib. Although these combinations have improved clinical outcome, resistance remains frequent, highlighting the need to identify vulnerabilities that enhance CDK4/6i response. To uncover metabolic dependencies associated with CDK4/6...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 70ebf8d7-17eb-5bf9-88be-d977ec6fbb04
DOI: 10.21203/rs.3.rs-10541704/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting the LIPH-CD36 axis potentiates CDK4/6 inhibition in ER+ breast cancerDOI 10.21203/rs.3.rs-10541704/v1Read

The impact of lipid metabolism on breast cancer: a review about its role in tumorigenesis and immune escapeSemantic proximity Read

ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer.Semantic proximity Read

The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assaysSemantic proximity Read

Targeting ferroptosis resistance resensitizes metastatic HR + HER2 − breast cancer cells to palbociclib‐hormone therapySemantic proximity Read

Key regulator PNPLA8 drives phospholipid reprogramming induced proliferation and migration in triple-negative breast cancer.Semantic proximity Read

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast CancerSemantic proximity Read

ENPP2 promotes progression and lipid accumulation via AMPK/SREBP1/FAS pathway in chronic lymphocytic leukemiaSemantic proximity Read

Glycolysis-mTORC1 crosstalk drives rapid proliferation in patient-derived endometrial cancer spheroids with ALDH activitySemantic proximity Read

Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancerSemantic proximity Read

Identification and validation of DHCR7 as a diagnostic biomarker involved in the proliferation and mitochondrial function of breast cancerSemantic proximity Read

Adaptive response to BET inhibition induces therapeutic vulnerability to MCL1 inhibitors in breast cancerSemantic proximity Read

Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancerSemantic proximity Read